Issue 43, 2022
From the journal:

RSC Advances

Self-fused concatenation of interferon with enhanced bioactivity, pharmacokinetics and antitumor efficacy†

Jin Hu, ORCID logo ‡*a   Jianquan Shi,‡b   Yeshuang Yuan,‡c   Shengjie Li,a   Bo Zhang,a   Haitao Dong,d   Qing Zhong,a   Qiu Xie,a   Xiaoyin Baie  and  Yingxing Lia  

* Corresponding authors

a Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China
E-mail: ncuskhujin@163.com

b Department of Intensive Care Unit, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China

c Department of Rheumatology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Clinical Immunology Center, Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100730, China

d Department of Stomatology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China

e Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing 100730, China

Abstract

We report an easy but universal protein modification approach, self-fused concatenation (SEC), to biosynthesize a set of interferon (IFN) concatemers with improved in vitro bioactivity, in vivo pharmacokinetics and therapeutic efficacy over the monomeric IFN, and the results can be positively enhanced by the concatenated number of self-fused proteins.

Graphical abstract: Self-fused concatenation of interferon with enhanced bioactivity, pharmacokinetics and antitumor efficacy

About
Cited by
Related
Download options Please wait...

Supplementary files

Article information

DOI
https://doi.org/10.1039/D2RA04978C
Article type
Paper
Submitted
09 Aug 2022
Accepted
28 Sep 2022
First published
04 Oct 2022
This article is Open Access
Creative Commons BY-NC license

RSC Adv., 2022,12, 28279-28282

Permissions

Request permissions

Self-fused concatenation of interferon with enhanced bioactivity, pharmacokinetics and antitumor efficacy

J. Hu, J. Shi, Y. Yuan, S. Li, B. Zhang, H. Dong, Q. Zhong, Q. Xie, X. Bai and Y. Li, RSC Adv., 2022, 12, 28279 DOI: 10.1039/D2RA04978C

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements